Semaglutide Patent Expiration

Semaglutide is used for treating Type 2 diabetes as an adjunct to diet and exercise to improve glycemic control in adults. It was first introduced by Novo Nordisk Inc in its drug Ozempic on Dec 5, 2017. Other drugs containing Semaglutide are Rybelsus, Wegovy.


Semaglutide Patents

Given below is the list of patents protecting Semaglutide, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Ozempic US10220155 Syringe device with a dose limiting mechanism and an additional safety mechanism Jul 17, 2026 Novo
Ozempic US10335462 Use of long-acting GLP-1 peptides Jun 21, 2033 Novo
Ozempic US10357616 Injection device with an end of dose feedback mechanism Jan 20, 2026 Novo
Ozempic US10376652 Automatic injection device with a top release mechanism Jan 20, 2026 Novo
Ozempic US11097063 Syringe device with a dose limiting mechanism and an additional safety mechanism Jul 17, 2026 Novo
Ozempic US11311679 Automatic injection device with a top release mechanism Jan 20, 2026 Novo
Ozempic US11446443 Injection device with torsion spring and rotatable display Oct 20, 2025 Novo
Ozempic US6899699 Automatic injection device with reset feature Jan 02, 2022

(Expired)

Novo
Ozempic US7762994 Needle mounting system and a method for mounting a needle assembly May 23, 2024

(Expired)

Novo
Ozempic US8114833 Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices Aug 13, 2025 Novo
Ozempic US8129343 Acylated GLP-1 compounds Dec 05, 2031 Novo
Ozempic US8536122 Acylated GLP-1 compounds Mar 20, 2026 Novo
Ozempic US8579869 Needle mounting system and a method for mounting a needle assembly Jun 30, 2023

(Expired)

Novo
Ozempic US8672898 Automatic injection device with reset feature Jan 02, 2022

(Expired)

Novo
Ozempic US8684969 Injection device with torsion spring and rotatable display Oct 20, 2025 Novo
Ozempic US8920383 Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left Jul 17, 2026 Novo
Ozempic US9108002 Automatic injection device with a top release mechanism Jan 20, 2026 Novo
Ozempic US9132239 Dial-down mechanism for wind-up pen Feb 01, 2032 Novo
Ozempic US9457154 Injection device with an end of dose feedback mechanism Sep 27, 2027 Novo
Ozempic US9457154 Injection device with an end of dose feedback mechanism Sep 29, 2027 Novo
Ozempic US9486588 Automatic injection device with reset feature Jan 02, 2022

(Expired)

Novo
Ozempic US9616180 Automatic injection device with a top release mechanism Jan 20, 2026 Novo
Ozempic US9687611 Injection device with torsion spring and rotatable display Feb 27, 2027 Novo
Ozempic US9775953 Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left Jul 17, 2026 Novo
Ozempic US9861757 Injection device with an end of dose feedback mechanism Jan 20, 2026 Novo
Ozempic USRE46363 Dial-down mechanism for wind-up pen Aug 03, 2026 Novo
Rybelsus US10086047 Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid Dec 16, 2031 Novo
Rybelsus US10278923 Oral dosing of GLP-1 compounds May 02, 2034 Novo
Rybelsus US10933120 Compositions of GLP-1 peptides and preparation thereof Mar 15, 2033 Novo
Rybelsus US10960052 Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl) amino) caprylic acid Dec 16, 2031 Novo
Rybelsus US11382957 Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid Dec 16, 2031 Novo
Rybelsus US11759501 Compositions of GLP-1 peptides and preparation thereof Mar 15, 2033 Novo
Rybelsus US11759502 Compositions of GLP-1 peptides and preparation thereof Mar 15, 2033 Novo
Rybelsus US11759503 Compositions of GLP-1 peptides and preparation thereof Mar 15, 2033 Novo
Rybelsus US8129343 Acylated GLP-1 compounds Dec 05, 2031 Novo
Rybelsus US8536122 Acylated GLP-1 compounds Mar 20, 2026 Novo
Rybelsus US9278123 Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid Dec 16, 2031 Novo
Wegovy US10888605 GLP-1 compositions and uses thereof Aug 24, 2038 Novo
Wegovy US11318191 GLP-1 compositions and uses thereof Feb 17, 2041 Novo
Wegovy US11752198 GLP-1 compositions and uses thereof Aug 24, 2038 Novo
Wegovy US12029779 Semaglutide in medical therapy Oct 10, 2038 Novo
Wegovy US8129343 Acylated GLP-1 compounds Dec 05, 2031 Novo
Wegovy US8536122 Acylated GLP-1 compounds Mar 20, 2026 Novo
Wegovy US9764003 Use of long-acting GLP-1 peptides Jun 21, 2033 Novo


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Semaglutide's patents.

Given below is the list recent legal activities going on the following patents of Semaglutide.

Event Date Patent/Publication
Patent litigations
Payment of Maintenance Fee, 4th Year, Large Entity 20 Jun, 2024 US10888605(Litigated)
Email Notification 20 Sep, 2023 US11759501
Email Notification 20 Sep, 2023 US11759503
Email Notification 20 Sep, 2023 US11759502
Mail Patent eGrant Notification 19 Sep, 2023 US11759502
Mail Patent eGrant Notification 19 Sep, 2023 US11759501
Sequence Moved to Public Database 19 Sep, 2023 US11759501
Patent Issue Date Used in PTA Calculation 19 Sep, 2023 US11759501
Recordation of Patent Grant Mailed 19 Sep, 2023 US11759501
Patent eGrant Notification 19 Sep, 2023 US11759501



Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳